Presentation is loading. Please wait.

Presentation is loading. Please wait.

Adverse events for rosuvastatin

Published byCornelius Osborne Modified over 6 years ago

Similar presentations

Presentation on theme: "Adverse events for rosuvastatin"— Presentation transcript:

1 Adverse events for rosuvastatin
AE Proportion (%)* Myopathy 12/872 (1.38) Rhabdomyolysis 38/872 (4.36) Renal failure 44/872 (5.05) *Rosuvastatin AEs divided by the total number of all serious and nonserious AEs from 1999 to 2004 for the six statin drugs in the marketplace Bennett WM, moderator. Forum. Postgraduate Education Course. Renal Week 2005; November 8-13, 2005; Philadelphia, PA.

2 Renal clearance of statins
Atorvastatin <2 Lovastatin 10 Simvastatin 13 Pravastatin 20 Cerivastatin 24 Rosuvastatin 28 Bennett WM, moderator. Forum. Postgraduate Education Course. Renal Week 2005; November 8-13, 2005; Philadelphia, PA.

Download ppt "Adverse events for rosuvastatin"

Similar presentations

Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.

Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.
RHABDOMYOLYSIS What you need to know. “Rhabdomyolysis is a common disorder which may result from a large variety of diseases, trauma, or toxic insults.

RHABDOMYOLYSIS What you need to know. “Rhabdomyolysis is a common disorder which may result from a large variety of diseases, trauma, or toxic insults.
Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.

Prescribing Information is available at the end of this presentation NHS Surrey Lipid Guidelines Dr Adam Jacques Ashford & St.
Clinical question: When do you get statin induced myopathy?

Clinical question: When do you get statin induced myopathy?
Anti-Hypercholesterolemic Agents  Biosynthesis and Metabolism of Cholesterol  What is arteriosclerosis? - Link between arteriosclerosis and cholesterol.

Anti-Hypercholesterolemic Agents  Biosynthesis and Metabolism of Cholesterol  What is arteriosclerosis? - Link between arteriosclerosis and cholesterol.
TM © 1999 Professional Postgraduate Services ® 0.60 0.70 0.80 0.90 1.00 4S: Total Mortality Reduction in a Subgroup of Patients With Diabetes Proportion.

TM © 1999 Professional Postgraduate Services ® S: Total Mortality Reduction in a Subgroup of Patients With Diabetes Proportion.
Drug Class Review Drug Effectiveness Review Project Marian McDonagh, PharmD Principal Investigator Statins and Fixed-dose Combination Products Containing.

Drug Class Review Drug Effectiveness Review Project Marian McDonagh, PharmD Principal Investigator Statins and Fixed-dose Combination Products Containing.
Clinical experience with ezetimibe/simvastatin in a Mediterranean population The SETTLE Study I. Migdalis a, A. Efthimiadis b, St. Pappas c, D. Alexopoulos.

Clinical experience with ezetimibe/simvastatin in a Mediterranean population The SETTLE Study I. Migdalis a, A. Efthimiadis b, St. Pappas c, D. Alexopoulos.
Kirk Mykytyn, Ph.D. Department of Pharmacology

Kirk Mykytyn, Ph.D. Department of Pharmacology
Background and Objective In the recently reported Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial, the combination of ezetimibe/simvastatin (E/S)

Background and Objective In the recently reported Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial, the combination of ezetimibe/simvastatin (E/S)
STATINS AGAIN. Atorvastatin Off patent Atorvastatin 40 = £36 PA Simvastatin 40 = £14 PA Atorvastatin 80 = £72 PA Simvastatin 80 = £24 PA.

STATINS AGAIN. Atorvastatin Off patent Atorvastatin 40 = £36 PA Simvastatin 40 = £14 PA Atorvastatin 80 = £72 PA Simvastatin 80 = £24 PA.
Slide 1 EZT 2002-W-6022-SS Ezetimibe Co-administered with Statins: Efficacy and Tolerability Copyright © 2003 MSP Singapore Company, LLC. All rights reserved.

Slide 1 EZT 2002-W-6022-SS Ezetimibe Co-administered with Statins: Efficacy and Tolerability Copyright © 2003 MSP Singapore Company, LLC. All rights reserved.
A New Statin Drug: A Brief History of My Career Bonny Ortolano, Ph.D. Genome Pharmaceuticals Cambridge, Massachusetts.

A New Statin Drug: A Brief History of My Career Bonny Ortolano, Ph.D. Genome Pharmaceuticals Cambridge, Massachusetts.
Non-Prescription Mevacor ® Merck & Co., Inc. New Drug Application 21-213 Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committee.

Non-Prescription Mevacor ® Merck & Co., Inc. New Drug Application Nonprescription Drugs and Endocrinologic and Metabolic Drugs Advisory Committee.
Pharmacoeconomics and Outcomes Research Dean G. Smith, Ph.D. October 10, 2005 UM Student Chapter.

Pharmacoeconomics and Outcomes Research Dean G. Smith, Ph.D. October 10, 2005 UM Student Chapter.
CS-1 CRESTOR ® Safety Howard G. Hutchinson, MD Vice President, Clinical Research.

CS-1 CRESTOR ® Safety Howard G. Hutchinson, MD Vice President, Clinical Research.
Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein.

Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein.
? OTC LOVASTATIN Jesse M. Polansky M.D., M.P.H. Representing self.

? OTC LOVASTATIN Jesse M. Polansky M.D., M.P.H. Representing self.
Statin Induce Myotoxicity

Statin Induce Myotoxicity
Jiří Slíva, M.D. statins (inhibitors of HMG-CoA reductase) fibrates anion - exchange resins nicotinic acid group.

Jiří Slíva, M.D. statins (inhibitors of HMG-CoA reductase) fibrates anion - exchange resins nicotinic acid group.

Similar presentations

Ads by Google